{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:08:23Z","timestamp":1794092903700,"version":"4.8.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jacadv.2025.101762","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:19:18Z","timestamp":1746271158000},"page":"101762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"P1","title":["Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice"],"prefix":"10.1016","volume":"4","author":[{"given":"Maria","family":"Alfarano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Ballatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Verardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Miraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Luigi","family":"Ciciarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Petramala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Letizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jacadv.2025.101762_bib1","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1210\/en.2006-0826","article-title":"Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects","volume":"147","author":"Funder","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.jacadv.2025.101762_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101762_bib3","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101762_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11906-000-0017-z","article-title":"Aldosterone and vascular damage","volume":"2","author":"Duprez","year":"2000","journal-title":"Curr Hypertens Rep"},{"issue":"10","key":"10.1016\/j.jacadv.2025.101762_bib5","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1097\/HJH.0000000000000284","article-title":"Oxidative stress in patients affected by primary aldosteronism","volume":"32","author":"Petramala","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacadv.2025.101762_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101762_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101762_bib8","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction and Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101762_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jacadv.2025.101762_bib10","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of Cardiology\/American Heart Association Joint Committee on clinical practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.jacadv.2025.101762_bib11","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"37","key":"10.1016\/j.jacadv.2025.101762_bib12","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101762_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cardfail.2004.03.002","article-title":"Aldosterone directly stimulates cardiac myocyte hypertrophy","volume":"10","author":"Okoshi","year":"2004","journal-title":"J Card Fail"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101762_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.004815","article-title":"Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue Doppler study","volume":"9","author":"Cesari","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jacadv.2025.101762_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/HJH.0000000000001534","article-title":"Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study","volume":"36","author":"Chen","year":"2018","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101762_bib16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCIMAGING.112.974576","article-title":"Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study","volume":"5","author":"Freel","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacadv.2025.101762_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism","volume":"62","author":"Rossi","year":"2013","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101762_bib18","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/HJH.0b013e3283550f93","article-title":"Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism","volume":"30","author":"Lin","year":"2012","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.jacadv.2025.101762_bib19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1291\/hypres.31.363","article-title":"Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis","volume":"31","author":"Hayashi","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jacadv.2025.101762_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10877","article-title":"Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases","volume":"7","author":"Cannavo","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101762_bib21","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/nm.2506","article-title":"Oxidation of CaMKII determines the cardiotoxic effects of aldosterone","volume":"17","author":"He","year":"2011","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101762_bib22","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCRESAHA.111.243956","article-title":"Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias","volume":"110","author":"Swaminathan","year":"2012","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.jacadv.2025.101762_bib23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101762_bib24","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebrovascular events in patients with primary aldosteronism","volume":"98","author":"Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101762_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101762_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.000018","article-title":"Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism","volume":"2","author":"McGraw","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"pt 1","key":"10.1016\/j.jacadv.2025.101762_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1469-7793.2001.0151k.x","article-title":"Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes","volume":"537","author":"B\u00e9nitah","year":"2001","journal-title":"J Physiol"},{"key":"10.1016\/j.jacadv.2025.101762_bib28","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101762_bib29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.hrthm.2009.02.005","article-title":"Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure","volume":"6","author":"Stambler","year":"2009","journal-title":"Heart Rhythm"},{"issue":"7","key":"10.1016\/j.jacadv.2025.101762_bib30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s11886-023-01888-5","article-title":"The role of MicroRNA in the myocarditis: a small actor for a great role","volume":"25","author":"Chimenti","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101762_bib31","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1210\/en.2016-1707","article-title":"Role and regulation of MicroRNAs in aldosterone-mediated cardiac injury and dysfunction in male rats","volume":"158","author":"Ball","year":"2017","journal-title":"Endocrinology"},{"issue":"7224","key":"10.1016\/j.jacadv.2025.101762_bib32","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101762_bib33","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/CIRCULATIONAHA.113.003863","article-title":"Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support","volume":"129","author":"Yang","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101762_bib34","doi-asserted-by":"crossref","first-page":"E1154","DOI":"10.1152\/ajpendo.00155.2018","article-title":"MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction","volume":"315","author":"Syed","year":"2018","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2-3","key":"10.1016\/j.jacadv.2025.101762_bib35","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10555-014-9497-1","article-title":"The developing story of Sprouty and cancer","volume":"33","author":"Masoumi-Moghaddam","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jacadv.2025.101762_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.767064","article-title":"MiR-21 in human cardiomyopathies","volume":"8","author":"Surina","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.jacadv.2025.101762_bib37","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1253\/circj.CJ-13-0557","article-title":"Cardiac dysfunction in mitochondrial disease. Clinical and molecular features","volume":"77","author":"Villar","year":"2013","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101762_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.497","article-title":"Adrenal \u03b2arrestin1 targeting for tobacco-associated cardiac dysfunction treatment: aldosterone production as the mechanistic link","volume":"7","author":"Solesio","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101762_bib39","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3390\/biomedicines9080946","article-title":"Aldosterone excess induced mitochondria decrease and dysfunction via mineralocorticoid receptor and oxidative stress in vitro and in vivo","volume":"9","author":"Tsai","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jacadv.2025.101762_bib40","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3109\/13880209.2015.1014569","article-title":"Inhibition of p38 MAPK activation protects cardiac mitochondria from ischemia\/reperfusion injury","volume":"53","author":"Kumphune","year":"2015","journal-title":"Pharm Biol"},{"key":"10.1016\/j.jacadv.2025.101762_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trsl.2021.08.003","article-title":"Aldosterone suppresses cardiac mitochondria","volume":"239","author":"Hung","year":"2022","journal-title":"Transl Res"},{"key":"10.1016\/j.jacadv.2025.101762_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2019.06.055","article-title":"Primary aldosteronism-associated cardiomyopathy: clinical-pathologic impact of aldosterone normalization","volume":"292","author":"Frustaci","year":"2019","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101762_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00395-013-0393-6","article-title":"Cardiac acquaporins","volume":"108","author":"Rutkovskiy","year":"2013","journal-title":"Basic Res Cardiol"},{"issue":"21","key":"10.1016\/j.jacadv.2025.101762_bib44","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/jcm10214854","article-title":"Myocardial aldosterone receptor and aquaporin 1 up-regulation is associated with cardiomyocyte remodeling in human heart failure","volume":"10","author":"Frustaci","year":"2021","journal-title":"J Clin Med"},{"issue":"16","key":"10.1016\/j.jacadv.2025.101762_bib45","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","article-title":"Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study","volume":"30","author":"Frustaci","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101762_bib46","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"30","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101762_bib47","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"34","key":"10.1016\/j.jacadv.2025.101762_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021694","article-title":"Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"10008","key":"10.1016\/j.jacadv.2025.101762_bib49","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.101762_bib50","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.jacadv.2025.101762_bib51","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacadv.2025.101762_bib52","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.jacadv.2025.101762_bib53","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.jacadv.2025.101762_bib54","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacadv.2025.101762_bib55","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMe1401231","article-title":"Lessons from the TOPCAT trial","volume":"370","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101762_bib56","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"22","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101762_bib57","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacadv.2025.101762_bib58","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacadv.2025.101762_bib59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.17925\/EE.2021.17.2.84","article-title":"Finerenone: a potential treatment for patients with chronic kidney disease and type 2 diabetes mellitus","volume":"17","author":"D'Marco","year":"2021","journal-title":"touchREV Endocrinol"},{"issue":"23","key":"10.1016\/j.jacadv.2025.101762_bib60","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jacadv.2025.101762_bib61","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101762_bib62","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101762_bib63","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2025.101762_bib64","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101762_bib65","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"16","key":"10.1016\/j.jacadv.2025.101762_bib66","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101762_bib67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacadv.2025.101762_bib68","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/HJH.0000000000002250","article-title":"Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY) study","volume":"38","author":"Seccia","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacadv.2025.101762_bib69","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","article-title":"Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jacadv.2025.101762_bib70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijcard.2016.12.029","article-title":"Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis","volume":"231","author":"Neefs","year":"2017","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2025.101762_bib71","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/europace\/euv366","article-title":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis","volume":"18","author":"Liu","year":"2016","journal-title":"Europace"},{"issue":"36","key":"10.1016\/j.jacadv.2025.101762_bib72","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101762_bib73","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.2174\/1381612826666200523171137","article-title":"Aldosterone and mineralocorticoid receptor antagonists on pulmonary hypertension and right ventricular failure: a review","volume":"26","author":"Omidkhoda","year":"2020","journal-title":"Curr Pharm Design"},{"issue":"2","key":"10.1016\/j.jacadv.2025.101762_bib74","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.113.007690","article-title":"Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis","volume":"130","author":"Maron","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101762_bib75","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"issue":"445","key":"10.1016\/j.jacadv.2025.101762_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap7294","article-title":"NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension","volume":"10","author":"Samokhin","year":"2018","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101762_bib77","doi-asserted-by":"crossref","first-page":"L315","DOI":"10.1152\/ajplung.00238.2021","article-title":"Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model","volume":"322","author":"Lu","year":"2022","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jacadv.2025.101762_bib78","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjcard.2013.04.051","article-title":"Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)","volume":"112","author":"Maron","year":"2013","journal-title":"Am J Cardiol"},{"issue":"38","key":"10.1016\/j.jacadv.2025.101762_bib79","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25001796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25001796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:56:47Z","timestamp":1750895807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25001796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2772963X25001796"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101762","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101762"}}